Long Term Follow-up for RGX-202

Part of paid clinical trials in Little Rock, Arkansas.

Sponsor
REGENXBIO Inc.
Study ID
NCT06491927
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
MALE
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • No Intervention — GENETIC
    Observational study

Study Details

RGX-202-5101 is a long-term follow up study that evaluates the long-term safety and efficacy of RGX-202 in participants who have received RGX-202 (an investigative gene therapy designed to deliver a transgene for novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain) in a separate parent study.

Key Dates

First listed
Jul 9, 2024
Start date
May 8, 2024
Status verified
Mar 2026
Primary completion
Dec 1, 2029
Completion
Dec 1, 2029

Study Design

Enrollment
66 participants (estimated)

Arms

  • Arm: RGX-202 Recipients
    Subjects who have received RGX-202 in a separate parent study.

Primary Outcome Measure

Evaluation of long-term safety of RGX-202 [ Time Frame: Baseline, 5 years inclusive of parent study ]

Locations (5)

FacilityCityStateZIPSite coordinators
Arkansas Children's HospitalLittle RockArkansas72202-
Stanford School of Medicine /Division of Neuromuscular MedicinePalo AltoCalifornia94304-
Ann & Robert H. Lurie Children's Hospital of ChicagoChicagoIllinois60611-
The University of Texas Southwestern Medical CenterDallasTexas75390-
Virginia Commonwealth UniversityRichmondVirginia23298-

Find similar trials in Little Rock, AR

By condition
Duchenne muscular dystrophy
By specialty
Pediatrics
By research site
Arkansas Children's Hospital· Little Rock, ARStanford School of Medicine /Division of Neuromuscular Medicine· Palo Alto, CAAnn & Robert H. Lurie Children's Hospital of Chicago· Chicago, ILThe University of Texas Southwestern Medical Center· Dallas, TXVirginia Commonwealth University· Richmond, VA

Related Studies